Turkey launches investigation into 19 pharma cos
Ankara: Turkey's competition authority said on Thursday it had launched an investigation into 19 pharmaceutical companies to determine whether they had violated competition law.
In a statement, the authority said it had decided on Nov. 9 to launch the probe into companies including AstraZeneca, Bayer, Glaxosmithkline, Johnson & Johnson, Bausch & Lomb, Sanofi and Pfizer. It provided no further details.
Asked about the matter, AstraZeneca said it does not comment on ongoing investigations as a matter of policy.
Glaxosmithkline, Sanofi and Germany's Merck KGaA all said they were fully cooperating with competition authorities in Turkey, but did not elaborate further.
In a statement, BASF said it was assessing the matter and was committed to high standards of legal compliance and business ethics.
AbbVie, Abdi Ibrahim, Bausch & Lomb, Bayer, Ilko, Johnson & Johnson, Liba, Menarini, Michael Page International, Panasonic, Pfizer, SIFI, and World Medicine could not immediately be reached for comment.
Read also: Misrepresentation of COVID vaccine efficacy: Texas Attorney General sues Pfizer
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.